Insider selling
Traded Nov 17 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $26K of Kura Oncology shares around Nov 17, 2026. The shares were not acquired as compensation.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Nov 17, 2026 · Notice filed Nov 17, 2026
A Kura Oncology officer told the SEC about a plan to sell $108K of Kura Oncology shares around Nov 17, 2026. The filing says the shares were acquired as compensation. That is a tiny part of all Kura Oncology shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider selling
Traded Nov 17 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $26K of Kura Oncology shares around Nov 17, 2026. The shares were not acquired as compensation.
Insider selling
Traded Nov 17 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $158K of Kura Oncology shares around Nov 17, 2026. The shares were not acquired as compensation. That is a tiny part of all Kura Oncology shares.
Insider buying
First insider buy since Sep 2025Traded Nov 13 · filed 4 days later
The CEO of Kura Oncology paid $754K out of pocket for Kura Oncology shares. It was the first purchase in 14 months. Shares held went up 21% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.